3. Umbruch 4.4..2005 - Online Pot

62 R.G. Pertwee
cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J
Pharm Pharmacol 27: 608–609
38 Karler R, Turkanis SA (1979) Cannabis and epilepsy. In: GG Nahas and WDM Paton (eds):
Marihuana: Biological Effects. Pergamon Press, Oxford, 619–641
39 Karler R, Turkanis SA (1981) The cannabinoids as potential antiepileptics. J Clin Pharmacol
(suppl) 21: 437S–448S
40 Karler R, Cely W, Turkanis SA (1974) Anticonvulsant activity of ∆ 9 -tetrahydrocannabinol and its
11-hydroxy and 8α, 11-dihydroxy metabolites in the frog. Res Commun Chem Pathol Pharmacol
9: 441–452
41 Banerjee SP, Snyder SH, Mechoulam R (1975) Cannabinoids: influence on neurotransmitter
uptake in rat brain synaptosomes. J Pharmacol Exp Ther 194: 74–81
42 Bisogno T, Hanusˇ L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB,
Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues:
effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Br J Pharmacol 134: 845–852
43 Bloom AS (1984) Effects of cannabinoids on neurotransmitter receptors in the brain. In: S Agurell,
WL Dewey and RE Willette (eds): The Cannabinoids: Chemical, Pharmacologic and Therapeutic
Aspects. Academic Press, Orlando, FL, 575–589
44 Bloom AS, Hillard CJ (1985) Cannabinoids, neurotransmitter receptors and brain membranes. In:
DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 217–231
45 Harris RA, Stokes JA (1982) Cannabinoids inhibit calcium uptake by brain synaptosomes. J
Neurosci 2: 443–447
46 Hershkowitz M, Goldman R, Raz A (1977) Effects of cannabinoids on neurotransmitter uptake,
ATPase activity and morphology of mouse brain synaptosomes. Biochem Pharmacol 26:
1327–1331
47 Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (–)-Cannabidiol antagonizes cannabinoid
receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99–106
48 Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of
natural cannabinoids: evidence for partial agonist activity of ∆ 9 -tetrahydrocannabinol and antagonist
activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1–PL6
49 Poddar MK, Dewey WL (1980) Effects of cannabinoids on catecholamine uptake and release in
hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 214: 63–67
50 Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected
cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid
receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989–999
51 Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998) Comparative receptor binding
analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285–292
52 Consroe P, Martin A, Mechoulam R (1985) Anticonvulsant effects of cannabidiol stereoisomers
and analogs in rats. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 705–712
53 Turkanis SA, Karler R (1975) Influence of anticonvulsant cannabinoids on post tetanic potentiation
of isolated Bullfrog ganglia. Life Sci 17: 569–578
54 Sandyk R, Consroe P, Stern L, Snider SR, Bliklen D (1988) Preliminary trial of cannabidiol in
Huntington’s Disease. In: G Chesher, P Consroe and R Musty (eds): Marihuana: An International
Research Report. Australian Gov. Publ. Service, Canberra, 157–162
55 Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991)
Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40:
701–708
56 Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement
disorders. Int J Neurosci 30: 277–282
57 Sandyk R, Snider SR, Consroe P, Elias SM (1986) Cannabidiol in dystonic movement disorders.
Psychiat Res 18: 291
58 Richter A, Löscher W (2002) Effects of pharmacological manipulations of cannabinoid receptors
on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol 454:
145–151
59 Zuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993) Effect of ipsapirone and cannabidiol on
human experimental anxiety. J Psychopharmacol 7: 82–88
60 Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000) Different effects of nabilone
and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66: 175–181